Skip to main content
logo
Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China flag China · Delayed Price · Currency is CNY
27.93
-0.15 (-0.53%)
Sep 18, 2025, 9:45 AM CST

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202018 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Adsorbed Tetanus Vaccine
535.78M
Log In
Log In
Log In
Log In
Upgrade
Adsorbed Tetanus Vaccine Growth
15.73%
Log In
Log In
Log In
Log In
Upgrade
Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine
26.42M
Log In
Log In
Log In
Log In
Upgrade
Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine Growth
580.49%
Log In
Log In
Log In
Log In
Upgrade
Influenzae Type B Haemophilus Conjugate Vaccine
23.50M
Log In
Log In
Log In
Log In
Upgrade
Influenzae Type B Haemophilus Conjugate Vaccine Growth
-13.82%
Log In
Log In
Log In
Log In
Upgrade
Refined Tetanus Toxoid Original Solution
404.53K
Log In
Log In
Log In
Log In
Upgrade
Refined Tetanus Toxoid Original Solution Growth
127.27%
Log In
Log In
Log In
Log In
Upgrade
Other
2.75M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
50.34%
Log In
Log In
Log In
Log In
Upgrade
Tetanus Toxoid Concentrated Liquid
-
Log In
Log In
Log In
Log In
Upgrade
Tetanus Toxoid Concentrated Liquid Growth
-
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202018 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
China
588.86M
Log In
Log In
Log In
Log In
Upgrade
China Growth
18.69%
Log In
Log In
Log In
Log In
Upgrade